International AIDS Conference

Two experimental HIV vaccine regimens failed to reduce infections in a 3-year trial in eastern and southern Africa compared with participants who were taking a placebo, some of whom were on oral PrEP, according to a study.

In June, the CDC began recommending doxycycline post-exposure prophylaxis — or doxy-PEP, as it is commonly known — as a prevention strategy for STIs in certain high-risk populations.

Testing HIV PrEP users for STIs every 6 months did not increase the risk for STIs compared with testing them every 3 months and could reduce the cost of PrEP programs, according to a study.

Three-quarters of people globally living with HIV are on ART, a roughly 30% increase during the last nine years, and fewer people acquired HIV in 2023 than at any point since the late 1980s, UNAIDS reported.

In June, Gilead Sciences announced that its investigational antiretroviral drug lenacapavir prevented 100% of new HIV infections during a phase 3 trial conducted among cisgender women in Africa.

Despite global progress toward eliminating HIV — including a growing number of nations that have hit goals to diagnose and successfully treat patients — funding pullbacks threaten to add decades to the battle, according to a study.

Long-acting injectable PrEP is feasible and acceptable to both men and women, according to a study presented at the AIDS 2024 meeting in Munich.

A seventh person has potentially been cured of HIV after receiving a stem cell transplant to treat blood cancer, researchers announced on the eve of the 25th International AIDS Conference.